hotspot -WSS

hotspot

author：fashion 2025-10-01 18:34:41 - browse：247

Primary care exam 01 — ReCor Medical, a startup owned by Japanese company Otsuka Medical Devices, and Medtronic have run studies that showed renal denervation leads to a modest decrease in blood pressure. Adam Berry/Getty Images

The Food and Drug Administration approved a surgical system used to reduce blood pressure from Recor Medical, the company announced Wednesday. The treatment, called renal denervation, is controversial in the cardiology community due to its unclear efficacy.

Renal denervation is a treatment for patients who cannot manage standard doses of blood pressure medication — whether because the drugs aren’t effective enough for them, create overwhelming side effects, or become too cumbersome. The therapy, which is meant to be a one-time procedure, is administered via a catheter. Electrodes on the catheter then emit radiofrequency or ultrasound energy to block nerve signals from the kidneys that increase blood pressure.

The therapy, a simple procedure to reduce the blood pressure of millions of Americans, was once seen as a boon for cardiologists and device makers. But a large-scale clinical trial from Medtronic in 2014 called renal denervation’s efficacy into question, as it did not significantly reduce blood pressure compared to placebo treatments.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： In shift, Texas to cover initial consult for Afghan baby's gene therapy

explore

WSS

Community Health Systems hospitals under DOJ investigation

A solution to the after

6 phony surgeries that take placebo to the extreme

Medicare Advantage coverage denials need scrutiny, senators say

Medicare Advantage coverage denials need scrutiny, senators say

In utero gene editing: an explainer

knowledge

hotspot

leisure time

Medical records are filled with copy

A new nitrogen execution bill also undermines medical licensing

Apple is now the first public company to be valued at $3 trillion

Medicare Advantage coverage denials need scrutiny, senators say

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

JPM pitch from hospitals? Revenue streams outside of patient care

Medicare proposal to cover medical devices draws a mixed reaction

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

Medicare details structure of new drug price negotiation program

Profiling embryos to choose those with higher IQs is almost a reality

hotspot

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

With competition flaring, obesity drug hits goal in liver disease study

Stories you might have missed in 2023: health, science, medicine

Alabama IVF ruling threatens families facing fatal genetic disease

FDA early review: GLP

Physician assistants need a new name. Here's what it should be

Wikipedia

explore

hotspot

leisure time